UY35573A - Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b - Google Patents

Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b

Info

Publication number
UY35573A
UY35573A UY35573A UY35573A UY35573A UY 35573 A UY35573 A UY 35573A UY 35573 A UY35573 A UY 35573A UY 35573 A UY35573 A UY 35573A UY 35573 A UY35573 A UY 35573A
Authority
UY
Uruguay
Prior art keywords
sulfamoilpirrolamida
hepatitis
derivatives
treatment
hbv
Prior art date
Application number
UY35573A
Other languages
English (en)
Inventor
Haché Geerwin Yvonne Paul
Mc Gowan David Craig
Vandyck Koen
Rombouts Geert
Verschueren Wim Gaston
Raboisson Pierre Jean-Marie
Last Stefaan Julien
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of UY35573A publication Critical patent/UY35573A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

DERIVADOS DE SULFAMOILPIRROLAMIDA Y SU USO COMO M EDICAMENTOS PARA EL TRATAMIENTO DE LA HEPATITIS B Inhibidores de la replicación del VHB 5 de Fórmula (ID) que incluyen las formas estereoquímicamente isoméricas y sales, hidratos y solvatos de esto s, donde X, Ra-Rd y R4- 10 R6 tienen los significados que se definen en la presente. La presente invención también se refiere a procesos para prepa rar dichos compuestos, a composiciones farmacéuti cas que los contienen y a su uso, solo o combinad o con otros inhibidores del VHB, en la terapia 15 contra el VHB.
UY35573A 2013-05-17 2014-05-16 Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b UY35573A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP13168291 2013-05-17
EP13175181 2013-07-04
EP13182281 2013-08-29
EP13191209 2013-10-31
EP13198160 2013-12-18
EP14157900 2014-03-05

Publications (1)

Publication Number Publication Date
UY35573A true UY35573A (es) 2014-11-28

Family

ID=50884356

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35573A UY35573A (es) 2013-05-17 2014-05-16 Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b

Country Status (35)

Country Link
US (3) US9884818B2 (es)
EP (3) EP3121164B1 (es)
JP (3) JP6318238B2 (es)
KR (4) KR20210025712A (es)
CN (2) CN105452220B (es)
AU (4) AU2014267220B2 (es)
BR (1) BR112015028461A2 (es)
CA (1) CA2909348C (es)
CL (1) CL2015003370A1 (es)
CY (2) CY1121391T1 (es)
DK (2) DK3121164T3 (es)
EA (1) EA037378B1 (es)
EC (1) ECSP15048122A (es)
ES (2) ES2787704T3 (es)
GT (1) GT201500312A (es)
HK (1) HK1218117A1 (es)
HR (2) HRP20181544T1 (es)
HU (2) HUE050236T2 (es)
IL (2) IL260597B (es)
JO (2) JO3603B1 (es)
LT (2) LT3121164T (es)
ME (1) ME03787B (es)
MX (3) MX2020011810A (es)
NI (1) NI201500161A (es)
PH (2) PH12015502579B1 (es)
PL (2) PL3121164T3 (es)
PT (2) PT2997011T (es)
RS (2) RS60285B1 (es)
SG (4) SG10201607293UA (es)
SI (2) SI3121164T1 (es)
TW (4) TW202126620A (es)
UA (1) UA117246C2 (es)
UY (1) UY35573A (es)
WO (1) WO2014184350A1 (es)
ZA (1) ZA201508443B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
JOP20130256B1 (ar) * 2012-08-28 2021-08-17 Janssenٍ Sciences Ireland Uc مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
EP3786162B1 (en) 2013-05-17 2023-08-09 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SI2997019T1 (sl) 2013-05-17 2018-12-31 Janssen Sciences Ireland Uc, Derivati sulfamoiliofenamida in njihova uporaba kot zdravila za zdravljenje hepatitisa B
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AP2016009122A0 (en) 2013-10-23 2016-03-31 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2792848T3 (es) 2014-02-05 2020-11-12 Novira Therapeutics Inc Politerapia para el tratamiento de infecciones por VHB
ES2705401T3 (es) * 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B
EP3974426A1 (en) 2014-03-13 2022-03-30 Indiana University Research and Technology Corporation Hepatitis b core protein allosteric modulators
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
LT3324977T (lt) 2015-07-22 2022-10-25 Enanta Pharmaceuticals, Inc. Benzodiazepino dariniai kaip rsv inhibitoriai
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
WO2017123884A1 (en) * 2016-01-15 2017-07-20 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AU2017231817B2 (en) * 2016-03-09 2021-02-25 Emory University Elimination of hepatitis B virus with antiviral agents
BR112018071048A2 (pt) * 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
BR112018075465A2 (pt) 2016-06-10 2019-03-19 Enanta Pharmaceuticals, Inc. agentes antivirais de hepatite b
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN109937201A (zh) 2016-09-15 2019-06-25 组装生物科学股份有限公司 乙型肝炎核心蛋白调节剂
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
TWI794190B (zh) 2016-11-07 2023-03-01 加拿大商愛彼特生物製藥公司 含有取代的吡啶酮之三環化合物及其使用方法
EA037576B1 (ru) * 2016-11-11 2021-04-15 Новира Терапьютикс, Инк. Комбинации и способы, включающие ингибитор сборки капсида
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
CN108341817B (zh) * 2017-01-23 2021-11-26 上海长森药业有限公司 硫脲类、脲类化合物及其用途
CN108341810B (zh) * 2017-01-23 2022-01-18 上海长森药业有限公司 环硫脲类化合物及其用途
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
US10358441B2 (en) 2017-02-16 2019-07-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018153326A1 (zh) * 2017-02-22 2018-08-30 上海长森药业有限公司 磺酰肼类化合物及其用途
MX2019010404A (es) 2017-03-02 2019-11-21 Assembly Biosciences Inc Compuestos sulfamida cíclicos y métodos de uso de los mismos.
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US11591334B2 (en) * 2017-05-04 2023-02-28 Shanghai Longwood Biopharmaceuticals Co., Ltd. Substituted pyrrolizines for the treatment of hepatitis B
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
BR112020004112A2 (pt) 2017-08-28 2020-09-24 Enanta Pharmaceuticals, Inc. agentes antiviras da hepatite b
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
MX2020004917A (es) 2017-11-13 2020-08-06 Enanta Pharm Inc Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona.
TW201927789A (zh) 2017-12-06 2019-07-16 美商因那塔製藥公司 B型肝炎抗病毒試劑
TW201936192A (zh) 2017-12-06 2019-09-16 美商因那塔製藥公司 B 型肝炎抗病毒試劑
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
CN111601788B (zh) * 2018-02-09 2022-06-14 正大天晴药业集团股份有限公司 衣壳蛋白装配抑制剂、其药物组合物和用途
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
CA3091339A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CA3094022A1 (en) 2018-03-30 2019-10-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
IL302865A (en) 2018-03-30 2023-07-01 Incyte Corp Use of JAK inhibitors to treat hidradenitis suppurativa
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
KR20210010878A (ko) 2018-05-16 2021-01-28 인펙스 테라퓨틱스 리미티드 항균 화합물
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
KR20210065965A (ko) 2018-09-21 2021-06-04 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서 작용화된 헤테로사이클
CN113195055A (zh) 2018-10-22 2021-07-30 组装生物科学股份有限公司 用于hbv治疗的5元杂芳基甲酰胺化合物
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
EP3873488A4 (en) 2018-10-31 2022-08-03 The University of Sydney COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION
CA3119973A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
EA202092159A1 (ru) 2019-01-25 2020-12-15 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение
JP2022521081A (ja) 2019-02-22 2022-04-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
JP7350871B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP2022524819A (ja) 2019-03-13 2022-05-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤固体製剤
UY38614A (es) 2019-03-18 2020-10-30 Enanta Pharm Inc Derivados de benzodiazepinas como inhibidores del rsv
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202103698A (zh) 2019-04-18 2021-02-01 美商健生醫藥公司 用於治療b型肝炎病毒感染之組合療法
WO2020214974A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20220241208A1 (en) 2019-05-24 2022-08-04 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of hbv
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TWI772823B (zh) 2019-06-18 2022-08-01 愛爾蘭商健生科學愛爾蘭無限公司 B型肝炎病毒(hbv)疫苗與蛋白殼組裝調節劑之組合
WO2020255013A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US20230012560A1 (en) * 2019-09-04 2023-01-19 Taigen Biotechnology Co., Ltd. Hepatitis b antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP7398556B2 (ja) 2019-09-30 2023-12-14 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖワクチン及びｈｂｖを治療する方法
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2022003984A (es) 2019-10-04 2022-07-27 Enanta Pharm Inc Compuestos heterociclicos antivirales.
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US20230151027A1 (en) * 2020-02-11 2023-05-18 Ospedale San Raffaele S.R.L. Spirocyclic inhibitors of hepatitis b virus
WO2021170741A1 (en) 2020-02-27 2021-09-02 Janssen Sciences Ireland Unlimited Company Treatment of hbv
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
TW202200161A (zh) 2020-03-20 2022-01-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
EP4139000A1 (en) 2020-04-22 2023-03-01 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
US20230183213A1 (en) 2020-04-22 2023-06-15 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
MX2022015221A (es) 2020-06-02 2023-03-08 Incyte Corp Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US20220119426A1 (en) 2020-08-07 2022-04-21 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230118118A (ko) 2020-12-08 2023-08-10 인사이트 코포레이션 백반증의 치료를 위한 jak1 경로 저해제
WO2022206879A1 (zh) * 2021-03-31 2022-10-06 苏州晶云药物科技股份有限公司 氨磺酰基吡咯酰胺类化合物的晶型及其制备方法
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164183A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
EP0135545A1 (en) 1983-02-19 1985-04-03 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd ４，５−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (es) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
AU2534295A (en) 1994-05-27 1995-12-21 James Black Foundation Limited Gastrin and cck antagonists
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
WO1997049695A1 (en) 1996-06-25 1997-12-31 Smithkline Beecham P.L.C. Sulfonamide derivatives as 5ht7 receptor antagonists
AU5127098A (en) 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
CA2325638A1 (en) 1998-03-26 1999-09-30 Hideki Yamada Amide derivatives and nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
DK1147089T3 (da) 1999-01-15 2006-04-10 Altana Pharma Ag Phenylphenanthridiner med PDE-IV-inhiberende virkning
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
ES2302697T3 (es) 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
CA2396087A1 (en) 1999-12-28 2001-07-19 Louis Stanley Chupak Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001055121A1 (fr) 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Dérivés d'azépine
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
ES2254324T3 (es) 2000-12-27 2006-06-16 Dainippon Sumitomo Pharma Co., Ltd. Compuestos de carbapenemo, medicamento y antibacteriano que los comprende y sus usos.
AU2002248418A1 (en) 2001-02-09 2002-08-28 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
PL368109A1 (en) 2001-04-19 2005-03-21 2-iminopyrrolidine derivates
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
SE0102315D0 (sv) * 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
DE60204718T2 (de) 2001-11-20 2006-05-18 Eli Lilly And Co., Indianapolis 3-substituierte oxindol beta 3 agonisten
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200410671A (en) 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
WO2004010943A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
WO2004014428A1 (ja) 2002-08-09 2004-02-19 Ajinomoto Co.,Inc. 腸疾患および内臓痛の治療薬
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
WO2004058709A1 (en) 2002-12-23 2004-07-15 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
ES2378620T3 (es) 2003-03-27 2012-04-16 Cytokinetics, Inc. Sulfonamidas para el tratamiento de insuficiencia cardiaca congestiva, sus composiciones y usos.
EP1628970A2 (en) 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
CA2525124A1 (en) 2003-05-13 2004-11-25 Schering Corporation Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2005087217A1 (en) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
WO2005115374A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for therapeutic use
ATE444066T1 (de) 2004-06-22 2009-10-15 Schering Corp Liganden für den cannabinoidrezeptoren
PL1773768T3 (pl) 2004-07-30 2019-03-29 Exelixis, Inc. Pochodne pirolu jako środki farmaceutyczne
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ553087A (en) 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
WO2006044457A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
US7608723B2 (en) 2004-10-19 2009-10-27 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
AU2005317870A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
JP2009508835A (ja) 2005-09-16 2009-03-05 アロー セラピューティクス リミテッド ビフェニル誘導体及びｃ型肝炎の治療におけるその使用
CA2633541A1 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
JP2009521452A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
US20090018118A1 (en) 2005-12-29 2009-01-15 Uros Urleb Heterocyclic compounds
US8609668B2 (en) 2006-05-04 2013-12-17 Philadelphia Health & Education Corporation Substituted triazolo[1,5-A]pyrimidines as antiviral agents
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
US20100016310A1 (en) 2006-08-17 2010-01-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
EP2076492A4 (en) 2006-10-06 2010-12-22 Merck Sharp & Dohme NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
EP2091527B1 (en) 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
CA2686382C (en) 2007-05-04 2013-09-17 Irm Llc Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
CL2008001631A1 (es) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
CN101328169B (zh) 2007-06-18 2011-05-25 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
CA2695071A1 (en) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag The use of benzamide derivatives for the treatment of cns disorders
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
EP2280001B1 (en) 2008-04-24 2014-10-15 Msd K.K. Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8299096B2 (en) 2008-06-26 2012-10-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
CA2735392A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
US9040488B2 (en) 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
EP2362775B1 (en) 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
WO2010065782A1 (en) 2008-12-04 2010-06-10 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
BRPI1010909A2 (pt) 2009-05-19 2015-09-08 Bayer Cropscience Ag "inseticida arilpirrolinas"
TWI671297B (zh) 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
EP2448410A4 (en) 2009-06-30 2013-12-18 Siga Technologies Inc TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
JP2013522192A (ja) 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための化合物
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
SI2566327T1 (sl) 2010-05-07 2017-07-31 Glaxosmithkline Llc Indoli
WO2011155898A1 (en) 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
US20130142827A1 (en) 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
CN103052406A (zh) 2010-07-19 2013-04-17 印斯拜尔药品股份有限公司 双官能rho激酶抑制剂化合物、组合物及应用
JP2013536178A (ja) 2010-07-26 2013-09-19 ニューロセラピューティクス ファーマ， インコーポレイテッド アリールスルホンアミド誘導体、組成物、および使用方法
CA2803689A1 (en) 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
CN103889428A (zh) 2010-10-04 2014-06-25 肝炎与病毒研究所 乙型肝炎病毒抗原分泌的新型抑制剂
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
ES2887303T3 (es) 2011-04-08 2021-12-22 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para el tratamiento de infecciones víricas
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2726459B1 (en) * 2011-07-01 2019-09-11 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
EA026977B1 (ru) 2012-01-06 2017-06-30 Янссен Сайенсиз Айрлэнд Юси 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112014021498A2 (pt) 2012-02-29 2017-07-18 Institute For Hepatitis And Virus Res composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013144129A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN104395330B (zh) 2012-05-25 2018-03-13 爱尔兰詹森科学公司 尿嘧啶基螺氧杂环丁烷核苷
CA2874828A1 (en) 2012-06-01 2013-12-05 Drexel University Modulation of hepatitis b virus cccdna transcription
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
EA026957B1 (ru) 2012-08-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
JOP20130256B1 (ar) 2012-08-28 2021-08-17 Janssenٍ Sciences Ireland Uc مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
PE20150776A1 (es) 2012-09-10 2015-05-21 Hoffmann La Roche 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
EA201591220A1 (ru) 2012-12-27 2016-01-29 Дрексел Юниверсити Новые противовирусные агенты против инфекции вирусом гепатита в
KR102190597B1 (ko) 2013-02-28 2020-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 테트라하이드로이미다조[1,5-d][1,4]옥사제핀 유도체
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014267198A1 (en) 2013-05-17 2015-11-05 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
SI2997019T1 (sl) 2013-05-17 2018-12-31 Janssen Sciences Ireland Uc, Derivati sulfamoiliofenamida in njihova uporaba kot zdravila za zdravljenje hepatitisa B
ES2654161T3 (es) 2013-05-28 2018-02-12 Astrazeneca Ab Compuestos químicos
EA201501142A1 (ru) 2013-05-28 2016-05-31 Байер Кропсайенс Акциенгезельшафт Гетероциклические соединения в качестве средств для борьбы с вредителями
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
EP3057592B1 (en) 2013-10-18 2019-05-22 Indiana University Research and Technology Corporation Hepatitis b viral assembly effectors
AP2016009122A0 (en) 2013-10-23 2016-03-31 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9115113B2 (en) 2013-11-14 2015-08-25 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2721001T3 (es) 2014-01-31 2019-07-26 Cognition Therapeutics Inc Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
ES2792848T3 (es) 2014-02-05 2020-11-12 Novira Therapeutics Inc Politerapia para el tratamiento de infecciones por VHB
ES2705401T3 (es) 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B
CR20160337A (es) 2014-03-07 2016-09-20 Hoffmann La Roche Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
EP3974426A1 (en) 2014-03-13 2022-03-30 Indiana University Research and Technology Corporation Hepatitis b core protein allosteric modulators
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
SG11201605896WA (en) 2014-03-28 2016-08-30 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
BR112016028000B1 (pt) 2014-05-30 2022-05-17 Qilu Pharmaceutical Co., Ltd Derivado de alça de di-hidropirimido como um inibidor de hbv
WO2016089990A1 (en) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
RU2742305C2 (ru) 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
CN107922377A (zh) 2015-04-17 2018-04-17 美国印第安纳大学研究和技术公司 乙肝病毒组装效应子
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
KR20180066279A (ko) 2018-06-18
PH12018501812A1 (en) 2019-11-18
US20200039931A1 (en) 2020-02-06
SG10201607294SA (en) 2016-10-28
CA2909348C (en) 2019-01-08
KR20160008574A (ko) 2016-01-22
ES2699261T3 (es) 2019-02-08
CY1121391T1 (el) 2020-05-29
ECSP15048122A (es) 2017-02-24
EP3594204A1 (en) 2020-01-15
MX2015015770A (es) 2016-03-11
PL2997011T3 (pl) 2019-03-29
MX2020011810A (es) 2021-10-21
HRP20200648T1 (hr) 2020-07-10
AU2014267220A1 (en) 2015-11-05
AU2019236657A1 (en) 2019-10-17
TW201522305A (zh) 2015-06-16
DK3121164T3 (da) 2020-05-11
EP2997011A1 (en) 2016-03-23
JP2020117530A (ja) 2020-08-06
AU2014267220B2 (en) 2017-09-28
EP3121164B1 (en) 2020-02-19
UA117246C2 (uk) 2018-07-10
KR102055639B1 (ko) 2019-12-13
IL264541A (en) 2019-02-28
RS58140B1 (sr) 2019-02-28
TWI684586B (zh) 2020-02-11
AU2019236657B2 (en) 2021-05-20
JP2016518434A (ja) 2016-06-23
PT2997011T (pt) 2018-11-30
HK1218117A1 (zh) 2017-02-03
CL2015003370A1 (es) 2016-05-27
TW202126620A (zh) 2021-07-16
ES2787704T3 (es) 2020-10-16
TWI733288B (zh) 2021-07-11
AU2021206827A1 (en) 2021-08-12
JO3583B1 (ar) 2020-07-05
NI201500161A (es) 2016-01-06
PL3121164T3 (pl) 2020-07-27
DK2997011T3 (en) 2018-12-17
RS60285B1 (sr) 2020-06-30
JO3603B1 (ar) 2020-07-05
TWI651300B (zh) 2019-02-21
CN105452220B (zh) 2019-01-25
HUE039997T2 (hu) 2019-02-28
CN110003076A (zh) 2019-07-12
AU2017276170A1 (en) 2018-01-18
IL264541B (en) 2019-09-26
SI2997011T1 (sl) 2018-11-30
SG10201607293UA (en) 2016-10-28
SG11201509428PA (en) 2015-12-30
MX366722B (es) 2019-07-22
NZ713201A (en) 2021-03-26
CY1123298T1 (el) 2021-12-31
HRP20181544T1 (hr) 2018-11-30
CN105452220A (zh) 2016-03-30
PH12015502579A1 (en) 2016-02-29
US20180141905A1 (en) 2018-05-24
LT2997011T (lt) 2018-10-25
US20160115125A1 (en) 2016-04-28
IL260597B (en) 2019-03-31
ME03787B (me) 2021-04-20
PT3121164T (pt) 2020-05-12
TW201908289A (zh) 2019-03-01
EP3121164A1 (en) 2017-01-25
HUE050236T2 (hu) 2020-11-30
CA2909348A1 (en) 2014-11-20
KR101867898B1 (ko) 2018-06-15
JP6318238B2 (ja) 2018-04-25
EA037378B1 (ru) 2021-03-22
SG10202002604PA (en) 2020-05-28
EA201592200A1 (ru) 2016-03-31
SI3121164T1 (sl) 2020-06-30
EP2997011B1 (en) 2018-08-29
TW202017903A (zh) 2020-05-16
KR20190139328A (ko) 2019-12-17
LT3121164T (lt) 2020-08-10
US9884818B2 (en) 2018-02-06
JP2018118990A (ja) 2018-08-02
GT201500312A (es) 2018-01-17
KR102223535B1 (ko) 2021-03-08
US10457638B2 (en) 2019-10-29
BR112015028461A2 (pt) 2017-07-25
KR20210025712A (ko) 2021-03-09
AU2017276170B2 (en) 2019-07-11
WO2014184350A1 (en) 2014-11-20
PH12015502579B1 (en) 2016-02-29
MX2019008585A (es) 2019-09-19
ZA201508443B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
NI201500029A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
ECSP15014941A (es) Compuestos antivíricos para el vsr
MX366123B (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
PE20151979A1 (es) Compuestos quimicos
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2017001918A2 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
ECSP18056196A (es) Derivados de indano
CR20150584A (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
CR20150059A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20220915